Sign in
CompletedNo phase

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Key facts

Who runs it
Sanofi
Where
Finland and Germany11 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
2,078 people enrolled
Started
2 Oct 2023
Ended
15 Dec 2023
Type of study
Observational, 2 groups
Treatments tested
  • Quadrivalent Influenza Vaccine
  • High-Dose Quadrivalent Influenza Vaccine
Record updated
24 March 2025

Who can take part

Age
6 months and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • There are no formal inclusion criteria. Individuals who approach the site for vaccination and agree to receive a vaccination card will be included and vaccinated with the respective vaccine brand according to the country of their location, recommendations for the individual vaccines as well as national recommendations

Who cannot take part

  • -

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This EPSS will determine the vaccinee reporting rates (RRs) of suspected ADRs following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the NH influenza season 2023/24. The primary objective of this surveillance is to estimate the vaccinee reporting rate (RR) of suspected adverse drug reactions (ADRs) occurring within 7 days following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the Northern Hemisphere (NH) influenza season 2023/24. Study duration per participant 2 months (including 6 weeks for VC distribution 2 weeks for vaccinee reporting) following the first vaccination

The 2 groups in the trial

  • VaxigripTetra®

    Participant vaccinated with VaxigripTetra® as per routine clinical practice

    Treatment: Quadrivalent Influenza Vaccine

  • Efluelda®

    Participant vaccinated with Efluelda® as per routine clinical practice

    Treatment: High-Dose Quadrivalent Influenza Vaccine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High Dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2023/24
Record updated
24 March 2025